Viking Therapeutics Appoints New Chief Medical Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Leadership Expansion: Viking Therapeutics has appointed Hubert C. Chen, M.D. as Chief Medical Officer, bringing over 20 years of biotech experience in senior roles across various therapeutic areas, which is expected to enhance the company's clinical development and regulatory affairs.
- Clinical Program Advancement: Chen will oversee the clinical development of VK2735, a novel dual agonist currently in Phase 3 trials for obesity, and successful progression could help the company secure a leading position in the rapidly growing metabolic disease market.
- Innovative Drug Development: Viking is evaluating multiple candidates, including VK2809 and VK0214, with VK2809 showing significant reductions in LDL-C and liver fat in Phase 2 trials, while VK0214 demonstrated good safety and tolerability in a Phase 1 trial, indicating strong potential for market entry.
- Market Opportunity Capture: Chen emphasized that obesity and metabolic disorders represent significant health challenges, and Viking's robust R&D pipeline and scientific innovation aim to improve patient health, which is expected to drive long-term growth potential for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.230
Low
70.00
Averages
97.00
High
125.00
Current: 29.230
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics Targets $150 Billion Obesity Drug Market
- Massive Market Potential: The global market for obesity drugs is projected to reach $150 billion by 2035, with Viking Therapeutics developing both oral and injectable versions of its weight-loss candidate VK2735 to capitalize on this significant opportunity.
- Analyst Price Target Incentive: Truist Financial has set a price target of $83 for Viking, suggesting a potential 188% upside from its June 8 opening price of $28.75, reflecting market optimism regarding the drug's prospects.
- Clinical Trial Progress: The injectable version of VK2735 is currently in phase 3 trials, while the oral version is expected to enter phase 3 in Q3 2026, with successful approvals potentially generating substantial revenue for the company.
- Significant Financial Risks: Despite the attractive market outlook, Viking reported net losses of $109 million in 2024 and $359 million in 2025, and as a clinical-stage company without commercial products, investors must be cautious of potential trial failures.
See More
Viking Therapeutics Appoints New Chief Medical Officer
- Executive Appointment: Viking Therapeutics has appointed Hubert Chen as Chief Medical Officer, bringing over 20 years of leadership experience in drug discovery, clinical development, and regulatory strategy, which is expected to enhance the company's product development across multiple therapeutic areas.
- Previous Roles: Prior to joining Viking, Chen served as Chief Research and Development Officer at Loyal Animal Health and was President and Chief Scientific Officer at Forte Biosciences, experiences that will provide a strong professional background for his role at Viking.
- Market Reaction: In pre-market trading, VKTX shares were priced at $27.84, down 0.32% from the previous trading day, indicating a cautious market response to the new appointment, which may affect investor confidence.
- Strategic Implications: Chen's appointment not only strengthens Viking's leadership team but may also accelerate the advancement of its clinical projects, enhancing the company's competitiveness in the biopharmaceutical industry, particularly in new drug development.
See More
Viking Therapeutics Appoints New Chief Medical Officer
- Leadership Expansion: Viking Therapeutics has appointed Hubert C. Chen, M.D. as Chief Medical Officer, bringing over 20 years of biotech experience in senior roles across various therapeutic areas, which is expected to enhance the company's clinical development and regulatory affairs.
- Clinical Program Advancement: Chen will oversee the clinical development of VK2735, a novel dual agonist currently in Phase 3 trials for obesity, and successful progression could help the company secure a leading position in the rapidly growing metabolic disease market.
- Innovative Drug Development: Viking is evaluating multiple candidates, including VK2809 and VK0214, with VK2809 showing significant reductions in LDL-C and liver fat in Phase 2 trials, while VK0214 demonstrated good safety and tolerability in a Phase 1 trial, indicating strong potential for market entry.
- Market Opportunity Capture: Chen emphasized that obesity and metabolic disorders represent significant health challenges, and Viking's robust R&D pipeline and scientific innovation aim to improve patient health, which is expected to drive long-term growth potential for the company.
See More
Viking Therapeutics Appoints New Chief Medical Officer
- New Chief Medical Officer: Viking Therapeutics has appointed Hubert C. Chen, M.D. as Chief Medical Officer, bringing over 20 years of leadership experience in drug discovery, clinical development, and regulatory strategy, reporting directly to CEO Brian Lian and overseeing clinical development and medical affairs.
- Advancing Clinical Programs: Dr. Chen's appointment comes at a critical time as Viking moves VK2735 through late-stage development, indicating the company's strategic focus on obesity and metabolic disorders and preparing for potential commercialization.
- Extensive Industry Experience: Prior to joining Viking, Dr. Chen served as Chief Research and Development Officer at Loyal Animal Health, where he led the first FDA-negotiated effectiveness and safety requirements for longevity therapeutics, showcasing his deep expertise in the biotech sector.
- Innovative Therapy Pipeline: Viking is advancing multiple clinical programs, including VK2735 and VK2809, with the former showing promising safety and tolerability in Phase 3 trials for obesity, highlighting the company's potential in developing innovative therapies.
See More
Analyst Optimistic on Viking Therapeutics' Future Potential
- Significant Price Target: Truist Financial analyst sets an $83 price target for Viking Therapeutics, representing a 188% increase from the June 8 opening price of $28.75, reflecting market optimism about its potential drug VK2735.
- Clinical Trial Progress: VK2735 is currently in phase 3 trials, with the injectable version underway and the oral version expected to enter phase 3 in Q3 2026, which could significantly enhance the company's competitive position if successful.
- Massive Market Potential: Morgan Stanley projects the global obesity drug market to grow from $15 billion in 2024 to $150 billion by 2035, with Viking Therapeutics actively developing VK2735 to capture market share in an increasingly crowded space.
- Significant Financial Risks: Despite potential market opportunities, Viking has yet to generate revenue, reporting a net loss of $109 million in 2024 and increasing to $359 million in 2025, with a cash burn of $103 million in just three months, necessitating cautious investor consideration of future uncertainties.
See More
Buffett's Investment Strategy and Healthcare Opportunities
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over 60 years by focusing on industries and companies with competitive advantages, and new CEO Greg Abel has pledged to continue this investment philosophy.
- Healthcare Sector Absence: Despite a diverse portfolio, Berkshire Hathaway is almost entirely absent from the healthcare sector, holding only kidney care giant DaVita, which Buffett added in 2011, while Abel closed the position in UnitedHealth Group in Q1 this year.
- Healthcare Investment Opportunities: The healthcare industry offers a wide range of investment options, with aggressive investors potentially targeting high-growth pharmaceutical companies like Eli Lilly, while conservative investors may prefer dividend-paying companies like Johnson & Johnson and Abbott Laboratories for steady earnings growth.
- Independent Investment Decisions: While it is valuable to follow the investment decisions of Buffett and Abel, investors should also consider the high-potential healthcare sector and make independent investment choices to capitalize on growth opportunities in this field.
See More
Viking Therapeutics Targets $150 Billion Obesity Drug Market
- Massive Market Potential: The global market for obesity drugs is projected to reach $150 billion by 2035, with Viking Therapeutics developing both oral and injectable versions of its weight-loss candidate VK2735 to capitalize on this significant opportunity.
- Analyst Price Target Incentive: Truist Financial has set a price target of $83 for Viking, suggesting a potential 188% upside from its June 8 opening price of $28.75, reflecting market optimism regarding the drug's prospects.
- Clinical Trial Progress: The injectable version of VK2735 is currently in phase 3 trials, while the oral version is expected to enter phase 3 in Q3 2026, with successful approvals potentially generating substantial revenue for the company.
- Significant Financial Risks: Despite the attractive market outlook, Viking reported net losses of $109 million in 2024 and $359 million in 2025, and as a clinical-stage company without commercial products, investors must be cautious of potential trial failures.
See More
Viking Therapeutics Appoints New Chief Medical Officer
- Executive Appointment: Viking Therapeutics has appointed Hubert Chen as Chief Medical Officer, bringing over 20 years of leadership experience in drug discovery, clinical development, and regulatory strategy, which is expected to enhance the company's product development across multiple therapeutic areas.
- Previous Roles: Prior to joining Viking, Chen served as Chief Research and Development Officer at Loyal Animal Health and was President and Chief Scientific Officer at Forte Biosciences, experiences that will provide a strong professional background for his role at Viking.
- Market Reaction: In pre-market trading, VKTX shares were priced at $27.84, down 0.32% from the previous trading day, indicating a cautious market response to the new appointment, which may affect investor confidence.
- Strategic Implications: Chen's appointment not only strengthens Viking's leadership team but may also accelerate the advancement of its clinical projects, enhancing the company's competitiveness in the biopharmaceutical industry, particularly in new drug development.
See More
Viking Therapeutics Appoints New Chief Medical Officer
- Leadership Expansion: Viking Therapeutics has appointed Hubert C. Chen, M.D. as Chief Medical Officer, bringing over 20 years of biotech experience in senior roles across various therapeutic areas, which is expected to enhance the company's clinical development and regulatory affairs.
- Clinical Program Advancement: Chen will oversee the clinical development of VK2735, a novel dual agonist currently in Phase 3 trials for obesity, and successful progression could help the company secure a leading position in the rapidly growing metabolic disease market.
- Innovative Drug Development: Viking is evaluating multiple candidates, including VK2809 and VK0214, with VK2809 showing significant reductions in LDL-C and liver fat in Phase 2 trials, while VK0214 demonstrated good safety and tolerability in a Phase 1 trial, indicating strong potential for market entry.
- Market Opportunity Capture: Chen emphasized that obesity and metabolic disorders represent significant health challenges, and Viking's robust R&D pipeline and scientific innovation aim to improve patient health, which is expected to drive long-term growth potential for the company.
See More
Viking Therapeutics Appoints New Chief Medical Officer
- New Chief Medical Officer: Viking Therapeutics has appointed Hubert C. Chen, M.D. as Chief Medical Officer, bringing over 20 years of leadership experience in drug discovery, clinical development, and regulatory strategy, reporting directly to CEO Brian Lian and overseeing clinical development and medical affairs.
- Advancing Clinical Programs: Dr. Chen's appointment comes at a critical time as Viking moves VK2735 through late-stage development, indicating the company's strategic focus on obesity and metabolic disorders and preparing for potential commercialization.
- Extensive Industry Experience: Prior to joining Viking, Dr. Chen served as Chief Research and Development Officer at Loyal Animal Health, where he led the first FDA-negotiated effectiveness and safety requirements for longevity therapeutics, showcasing his deep expertise in the biotech sector.
- Innovative Therapy Pipeline: Viking is advancing multiple clinical programs, including VK2735 and VK2809, with the former showing promising safety and tolerability in Phase 3 trials for obesity, highlighting the company's potential in developing innovative therapies.
See More
Analyst Optimistic on Viking Therapeutics' Future Potential
- Significant Price Target: Truist Financial analyst sets an $83 price target for Viking Therapeutics, representing a 188% increase from the June 8 opening price of $28.75, reflecting market optimism about its potential drug VK2735.
- Clinical Trial Progress: VK2735 is currently in phase 3 trials, with the injectable version underway and the oral version expected to enter phase 3 in Q3 2026, which could significantly enhance the company's competitive position if successful.
- Massive Market Potential: Morgan Stanley projects the global obesity drug market to grow from $15 billion in 2024 to $150 billion by 2035, with Viking Therapeutics actively developing VK2735 to capture market share in an increasingly crowded space.
- Significant Financial Risks: Despite potential market opportunities, Viking has yet to generate revenue, reporting a net loss of $109 million in 2024 and increasing to $359 million in 2025, with a cash burn of $103 million in just three months, necessitating cautious investor consideration of future uncertainties.
See More
Buffett's Investment Strategy and Healthcare Opportunities
- Investment Legacy: Warren Buffett has led Berkshire Hathaway to market-beating returns over 60 years by focusing on industries and companies with competitive advantages, and new CEO Greg Abel has pledged to continue this investment philosophy.
- Healthcare Sector Absence: Despite a diverse portfolio, Berkshire Hathaway is almost entirely absent from the healthcare sector, holding only kidney care giant DaVita, which Buffett added in 2011, while Abel closed the position in UnitedHealth Group in Q1 this year.
- Healthcare Investment Opportunities: The healthcare industry offers a wide range of investment options, with aggressive investors potentially targeting high-growth pharmaceutical companies like Eli Lilly, while conservative investors may prefer dividend-paying companies like Johnson & Johnson and Abbott Laboratories for steady earnings growth.
- Independent Investment Decisions: While it is valuable to follow the investment decisions of Buffett and Abel, investors should also consider the high-potential healthcare sector and make independent investment choices to capitalize on growth opportunities in this field.
See More
